glp-1 obesity drug news today oct 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response 2024 was a record year

Description

A recent meta-analysis involving 32,884 patients from 19 randomized controlled trials further confirmed a 23% reduction in all-cause mortality associated with GLP-1RAs use (OR = 0.77) (Rivera et al., 2024)

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

cardiovascular disease, stroke, cognitive impairment and diabetic kidney disease

The guide on when weight loss begins on semaglutide gives context on where you are likely to be in the metabolic adjustment curve relative to a test, which helps you understand what side effects you might reasonably expect